We are live on ! Find out more
CCM

Copernicus Capital Management Portfolio holdings

AUM $8.26M
1-Year Est. Return 37.91%
This Fund
S&P 500
This Quarter Est. Return
+1.56%
1 Year Est. Return
+37.91%
3 Year Est. Return
+125.98%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$8.26M
AUM Growth
+$1.92M
Cap. Flow
+$1.73M
Cap. Flow %
20.93%
Top 10 Hldgs %
93.21%
Holding
21
New
10
Increased
2
Reduced
1
Closed
8

Top Buys

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$1.33M
2
TMO icon
Thermo Fisher Scientific
TMO
+$1.1M
3
TDOC icon
Teladoc Health
TDOC
+$1.02M
4
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$868K
5
JNJ icon
Johnson & Johnson
JNJ
+$853K

Top Sells

Rank Stock Value
1
VRTX icon
Vertex Pharmaceuticals
VRTX
+$1.81M
2
ATRA icon
Atara Biotherapeutics
ATRA
+$778K
3
ZNTL icon
Zentalis Pharmaceuticals
ZNTL
+$532K
4
TCRR
TCR2 Therapeutics Inc. Common Stock
TCRR
+$492K
5
ACCD
Accolade Inc
ACCD
+$380K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
2 Consumer Staples 0%
3 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PFE icon
1
Pfizer
PFE
$143B
$1.29M 15.61%
+30,000
New +$1.33M
TMO icon
2
Thermo Fisher Scientific
TMO
$213B
$1.14M 13.83%
+2,000
New +$1.1M
TDOC icon
3
Teladoc Health
TDOC
$1.56B
$888K 10.75%
+7,000
New +$1.02M
BMRN icon
4
BioMarin Pharmaceuticals
BMRN
$11.4B
$850K 10.29%
+11,000
New +$868K
JNJ icon
5
Johnson & Johnson
JNJ
$624B
$808K 9.78%
+5,000
New +$853K
FATE icon
6
Fate Therapeutics
FATE
$294M
$711K 8.6%
12,000
+2,000
+20% +$157K
HZNP
7
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$657K 7.95%
6,000
+1,000
+20% +$104K
RCUS icon
8
Arcus Biosciences
RCUS
$3.74B
$593K 7.18%
17,000
-3,000
-15% -$93.4K
ALLO icon
9
Allogene Therapeutics
ALLO
$628M
$386K 4.67%
+15,000
New +$356K
MDT icon
10
Medtronic
MDT
$105B
$376K 4.55%
+3,000
New +$388K
PRQR icon
11
ProQR Therapeutics
PRQR
$253M
$335K 4.05%
+40,000
New +$261K
IMTX icon
12
Immatics
IMTX
$1.27B
$130K 1.57%
+10,000
New +$127K
FOLD
13
DELISTED
Amicus Therapeutics
FOLD
$96K 1.16%
+10,000
New +$102K
ATRA icon
14
Atara Biotherapeutics
ATRA
$73.6M
– –
-2,000
Closed -$778K
JAZZ icon
15
Jazz Pharmaceuticals
JAZZ
$16B
– –
-2,000
Closed -$355K
SKIN icon
16
SkinHealth Systems
SKIN
$95.9M
– –
-10,000
Closed -$168K
VRTX icon
17
Vertex Pharmaceuticals
VRTX
$120B
– –
-9,000
Closed -$1.81M
ZNTL icon
18
Zentalis Pharmaceuticals
ZNTL
$317M
– –
-10,000
Closed -$532K
ACCD
19
DELISTED
Accolade Inc
ACCD
– –
-7,000
Closed -$380K
GRTS
20
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
– –
-35,000
Closed -$320K
TCRR
21
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
– –
-30,000
Closed -$492K

Similar funds

AAM
Areion Asset Management Hong Kong $7.82M AUM 16% 1-Year Est. Return
IR
Invictus RG Hamilton, Bermuda $8.9M AUM 56.32% 1-Year Est. Return
YEPV
Yorktown Energy Partners VI New York $6.21M AUM 74.4% 1-Year Est. Return
LC
Lunia Capital Dallas, Texas $4.49M AUM 42.82% 1-Year Est. Return
MA
MANA Advisors New York $3.06M AUM 7.13% 1-Year Est. Return
IFC
Intact Financial Corporation Toronto, Ontario, Canada $14M AUM
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
ARTA
A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return

Copernicus Capital Management's Q3 2021 Portfolio in Review

As of Q3 2021, Copernicus Capital Management held 21 positions worth $8.26M, up 30% from $6.34M the previous quarter. Its ten largest holdings account for 93% of the portfolio.

Copernicus Capital Management deployed $1.73M of net new capital in Q3 2021, opening 10 new positions and adding to 2 existing holdings. Its largest new stake was Pfizer: 30,000 shares worth $1.29M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 91% a quarter earlier, followed by Consumer Staples and Industrials.

On the sell side, the largest reduction was Arcus Biosciences, an estimated $93.4K trimmed.

  • Copernicus Capital Management's largest Q3 2021 buy was Pfizer: 30,000 shares worth $1.29M.
  • Copernicus Capital Management added most to Fate Therapeutics in Q3 2021, an estimated $157K increase.
  • Copernicus Capital Management's biggest Q3 2021 reduction was Arcus Biosciences, cutting an estimated $93.4K.
  • Copernicus Capital Management fully exited Vertex Pharmaceuticals in Q3 2021, selling an estimated $1.81M.
  • Copernicus Capital Management's ten largest holdings make up 93% of its $8.26M portfolio in Q3 2021.
  • Copernicus Capital Management opened 10 new positions and closed 8 in Q3 2021.
  • Copernicus Capital Management's portfolio value rose 30% quarter-over-quarter to $8.26M.

Based on Copernicus Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.